This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

As artificial intelligence spending continues to reshape the semiconductor landscape, investors are weighing the merits of NVIDIA Corp., Advanced Micro Devices Inc. and Intel Corp. in a high-stakes contest for dominance in data centers, AI accelerators and traditional computing. With NVIDIA maintaining its lead in AI GPUs, AMD gaining ground in both CPUs and GPUs, and Intel staging a notable recovery, the choice of which stock to buy in the second half of 2026 depends on growth outlook, valuation and risk tolerance.

NVIDIA shares closed recently around $205, with a market capitalization nearing $5 trillion. The company has delivered explosive growth, reporting record quarterly revenue of $81.6 billion in its most recent period, up 85% year-over-year, driven overwhelmingly by its data center segment. Analysts continue to view it as the clear leader in the AI infrastructure boom.

Oppenheimer analyst Rick Schafer has described NVIDIA as an “AI castle on a hill” that boasts the best performance-per-watt for both training and inference. He maintains an Outperform rating, highlighting the company’s Blackwell Ultra racks as leading the market by two generations.

AMD, trading near $500-$510 after a strong run, has seen significant outperformance in 2026 in some periods, fueled by accelerating data center growth and CPU share gains. Citi recently upgraded the stock to Buy with a $575 price target, citing underappreciated GPU opportunities, potential major wins with customers like Meta, and a CPU revival tied to agentic AI workloads. The firm sees AI potentially driving 54% of AMD’s sales by 2028.

Intel has staged one of the most dramatic recoveries, with shares more than doubling year-to-date at points amid optimism around its foundry ambitions, server CPU improvements and AI efforts under new leadership. Recent trading levels have hovered around $120-$125. While still facing execution challenges, the company benefits from broader CPU demand in the AI era.

The three companies operate in overlapping but distinct segments. NVIDIA dominates the high-margin AI accelerator market with an estimated 85-90% share, powered by its CUDA software ecosystem that creates strong customer lock-in. Its latest earnings underscored insatiable demand, with data center revenue continuing to surge.

AMD has successfully challenged NVIDIA in GPUs while maintaining leadership in certain server CPU segments, chipping away at Intel’s traditional stronghold. CEO Lisa Su has highlighted strong momentum in EPYC processors and Instinct GPUs, with the company raising expectations for server CPU market growth.

Intel, historically the CPU king, is fighting back with improved product roadmaps, foundry partnerships and AI chip initiatives. It has secured notable customer interest, though its turnaround remains a work in progress compared to the more established AI trajectories of its rivals.

Valuations reflect these dynamics. NVIDIA trades at forward multiples that some analysts consider attractive relative to its growth, especially compared to historical averages. AMD offers a balance of growth and somewhat more reasonable pricing in the eyes of bulls, while Intel’s valuation has expanded sharply with its rally but carries higher uncertainty.

Market watchers note that NVIDIA’s ecosystem advantage remains formidable. “They’ve got the whole stack,” one analyst observed in a recent discussion, pointing to CUDA, hardware and software integration. AMD is seen as the primary alternative for customers seeking options, while Intel’s path involves both CPU resilience and foundry scale.

Risks abound for all three. A potential slowdown in hyperscaler AI capital expenditure could pressure NVIDIA’s premium pricing. AMD faces the challenge of closing the performance gap in GPUs, and Intel must prove it can execute consistently on its ambitious restructuring. Broader economic factors, geopolitical tensions affecting supply chains, and competition from custom AI chips by big tech firms add layers of uncertainty.

For 2026 and beyond, analysts largely favor NVIDIA for its unmatched leadership and margins, with many maintaining Buy ratings and price targets implying further upside. AMD garners strong support as a high-conviction growth play with diversification benefits. Intel appeals to those betting on a multi-year turnaround and CPU/AI convergence.

Diversification across the sector remains a prudent approach for many portfolios, as the AI buildout is expected to benefit multiple players. NVIDIA’s near-term dominance appears secure, but AMD’s share gains and Intel’s recovery potential could shift the competitive balance over time.

Longer-term projections point to continued expansion in AI infrastructure, with data center spending driving semiconductor demand well into the decade. NVIDIA’s scale and innovation pipeline position it as the default leader, yet opportunities exist for AMD to carve out meaningful market share and for Intel to stabilize and grow in select areas.

Investors should consider their time horizon, risk appetite and overall portfolio allocation. Those seeking established AI leadership with strong cash flow generation may lean toward NVIDIA. Growth-oriented investors comfortable with volatility might favor AMD’s upside in both AI and traditional computing. Value-oriented or turnaround plays could look at Intel, though with higher execution risk.

The semiconductor sector’s cyclical nature means near-term pullbacks can create entry points, as seen in recent trading fluctuations. NVIDIA has pulled back from highs but remains a core holding for many AI-themed funds. AMD’s recent upgrades reflect growing confidence in its competitive positioning. Intel’s volatility underscores the binary nature of its recovery story.

Ultimately, no single stock is a guaranteed winner, but the trio represents the core of the AI and computing renaissance. NVIDIA sets the pace, AMD challenges aggressively, and Intel fights to reclaim relevance. Monitoring quarterly results, customer wins and technological benchmarks will be key to assessing which narrative prevails through the remainder of 2026 and into 2027.

As the AI investment wave matures, these chipmakers are poised to benefit, albeit at different rates and with varying levels of certainty. Prudent investors will weigh the structural advantages against valuations and competitive threats before committing capital in this dynamic market.

SACRAMENTO, Calif. — Influenza vaccination provided moderate protection during the severe 2024-25 flu season, with people who received the shot 40% less likely to test positive for the virus compared to those who did not, according to a large new study of more than 1.1 million Californians.

The analysis, published in JAMA Network Open, offers fresh evidence of the vaccine’s benefits amid one of the most intense flu seasons in recent memory, marked by record pediatric deaths and elevated hospitalizations nationwide.

Researchers from the California Department of Public Health examined data from individuals aged 6 months and older who were tested for influenza between Oct. 1, 2024, and May 31, 2025. The case-control study found clear associations between vaccination and reduced odds of both infection and severe outcomes.

“These findings are consistent with protection against severe and fatal influenza among people vaccinated against influenza,” the study authors wrote.

For adults aged 65 and older who tested positive for flu, vaccination was linked to 29% lower odds of dying from an influenza-related cause within 30 days of testing. This protection against mortality underscores the vaccine’s role in safeguarding the most vulnerable populations during peak transmission periods.

The 2024-25 season was classified as high severity, with the highest rate of influenza-associated hospitalizations in 24 years. Nationwide estimates cited in the study pointed to between 610,000 and 1.3 million hospitalizations and 27,000 to 130,000 deaths. Tragically, the flu claimed the lives of 289 children, surpassing the previous record from the 2009-2010 H1N1 pandemic season.

Public health officials have long emphasized annual vaccination as the primary tool for mitigating flu’s impact. The Centers for Disease Control and Prevention recommends everyone 6 months and older get vaccinated each season, noting that even when effectiveness is moderate, shots substantially reduce the risk of serious complications.

This latest California data aligns with broader national interim estimates from the 2024-2025 season, which showed vaccine effectiveness ranging from 32% to 60% against outpatient visits in different networks and 41% to 78% against hospitalizations in certain groups.

The study’s scale provides robust real-world evidence. By leveraging comprehensive testing and vaccination records in California’s large population, researchers could account for key variables while focusing on laboratory-confirmed cases, strengthening the reliability of the findings.

Experts note that flu vaccines work by prompting the immune system to produce antibodies against specific strains predicted to circulate. Because influenza viruses evolve rapidly, effectiveness varies annually depending on how well the vaccine matches circulating strains. During the 2024-25 season, predominant strains included influenza A viruses, against which protection was observed.

Beyond individual protection, vaccination contributes to community-level benefits by reducing overall transmission. Lower infection rates among vaccinated people mean fewer opportunities for the virus to spread to unvaccinated or high-risk individuals.

The findings come as health authorities prepare for the 2025-2026 season. Vaccine formulations are updated each year based on global surveillance data from the World Health Organization and national centers. Manufacturers typically produce hundreds of millions of doses, distributed through clinics, pharmacies and public health programs.

Despite consistent recommendations, vaccination coverage varies. Rates are typically higher among older adults and young children but lag in working-age adults. Barriers include access, misinformation, and perceptions that the flu is mild for healthy people — a view contradicted by hospitalization and death statistics.

The California study adds to a body of evidence accumulated over decades. Previous seasons have shown similar moderate effectiveness, with vaccines preventing millions of illnesses and tens of thousands of hospitalizations annually even in years with imperfect strain matches.

For older adults, who face the highest risk of severe outcomes, the 29% reduction in flu-related mortality is particularly meaningful. This group often has weakened immune responses, making any additional protection valuable. Enhanced vaccines, such as high-dose or adjuvanted formulations, are available specifically for those 65 and older.

Children also benefited significantly in the data. The record 289 pediatric deaths highlight the virus’s danger to younger age groups, where vaccination can prevent not only infection but also complications like secondary bacterial pneumonia or exacerbation of chronic conditions.

Broader context from the CDC indicates the 2024-25 season strained healthcare systems. High hospitalization rates, especially among the elderly and those with underlying conditions, led to increased emergency department visits and intensive care admissions in many regions.

Antiviral medications like oseltamivir (Tamiflu) remain an important treatment tool when administered early, but prevention through vaccination is the cornerstone of public health strategy. Combined with hygiene practices, staying home when sick, and masking in high-risk settings, shots form part of a layered defense.

Looking forward, ongoing research explores improved vaccines, including universal candidates targeting conserved parts of the virus to provide broader, longer-lasting protection. Until those become available, current annual shots offer the best available shield.

The study authors emphasized the importance of continued surveillance and high vaccination uptake. With flu seasons varying in intensity, consistent public health messaging helps maintain awareness even as other respiratory viruses like COVID-19 and RSV compete for attention.

Health officials urge eligible individuals to get vaccinated as soon as doses become available in the fall, ideally before peak season. For the 2025-2026 campaign, updated recommendations are expected from the CDC’s Advisory Committee on Immunization Practices.

This California research reinforces that while no vaccine is 100% effective, flu shots deliver meaningful protection against infection, severe disease and death. In a high-burden season, that 40% reduction in positivity translated to thousands of prevented cases and associated complications across the state.

As summer approaches and planning for the next respiratory virus season intensifies, the data serve as a timely reminder of vaccination’s value. Public health campaigns will likely highlight these results to encourage uptake, particularly among groups with historically lower coverage rates.

The findings also highlight the power of large-scale, real-world data analysis in evaluating vaccine performance. California’s comprehensive immunization information system enabled this detailed assessment, providing insights applicable beyond state borders.

In summary, the new evidence strengthens the case for annual influenza vaccination as a safe, effective measure that saves lives and reduces healthcare burden, even during particularly challenging seasons.